title: [Pharmacokinetic and clinical studies of flomoxef in perinatal period].
abstract: Pharmacokinetic and clinical studies of flomoxef (FMOX) in perinatal period were carried out and the following results were obtained. 1. Concentrations of FMOX in maternal serum, umbilical cord serum and amniotic fluid were determined subsequently to intravenous injection (4 cases) and intravenous drip infusion method (20 cases) of 1 g FMOX. Maternal serum levels were similar to those of healthy adults, and peak levels of umbilical cord sera and amniotic fluids were 12.0 micrograms/ml and 12.05 micrograms/ml, respectively, using intravenous drip infusion. The levels in amniotic fluids were higher than those in umbilical cord sera at 2 hours after treatment in either administration method. Parameters T 1/2 (beta) and AUC were 1.05 hours and 74.1 micrograms.hr/ml, respectively. 2. In the treatment of 4 cases with perinatal infection and in prophylaxis cases, clinical efficacies of FMOX were all good with 1 g twice daily treatment using intravenous drip infusion. No side effects nor abnormal laboratory test values due to the drug were observed in any cases. These results indicate that single intravenous drip infusion of FMOX 1-2 g twice daily is effective for the treatment and the prophylaxis of perinatal infections.
authors.affiliation: Department of Obstetrics and Gynecology, School of Medicine, Juntendo University.
authors.forename: S
authors.initials: S
authors.lastname: Matsuda
authors.forename: H
authors.initials: H
authors.lastname: Hirayama
authors.forename: K
authors.initials: K
authors.lastname: Oh
mesh_terms: D000328:Adult; D000653:Amniotic Fluid / Q000378:metabolism; D002511:Cephalosporins / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000627:therapeutic use; D002821:Chorioamnionitis / Q000517:prevention & control; D004716:Endometritis / Q000188:drug therapy / Q000378:metabolism; D005260:Female; D005312:Fetal Blood / Q000378:metabolism; D006801:Humans; D007262:Infusions, Intravenous; D007275:Injections, Intravenous; D008413:Mastitis / Q000188:drug therapy / Q000378:metabolism; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000188:drug therapy* / Q000378:metabolism; D011645:Puerperal Infection / Q000188:drug therapy* / Q000378:metabolism
chemical_list: D002511:Cephalosporins; C045693:flomoxef